• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

david.goode@unimelb.edu.au

Credentials


Position
Honorary (Senior Fellow)
The Sir Peter MacCallum Department of Oncology
ORCID

0000-0002-3277-6562

Dr David Goode

Honorary (Senior Fellow)
The Sir Peter MacCallum Department of Oncology

69 Scholarly works
7 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Putative breast cancer risk variants from populations of South Asian ancestry are under-represented in public variant classification databases
    DOI: 10.1186/s13058-025-02166-8
  • 2025

    Journal article

    Single-cell transcriptomics redefines focal neuroendocrine differentiation as a distinct prostate cancer pathology
    DOI: 10.1002/1878-0261.70099
  • 2024

    Journal article

    Disruption of metazoan gene regulatory networks in cancer alters the balance of co-expression between genes of unicellular and multicellular origins
    DOI: 10.1186/s13059-024-03247-1
  • 2021

    Research grants (international)

    Identifying Genetic, Transcriptional and Microenvironment Drivers of Lethal Prostate Cancer for Better Patient Stratification, Disease Tracking and Drug Target Discovery
  • 2021

    Research grants (ARC, NHMRC, MRFF)

    Evaluating Clinically Relevant Biomarkers to Improve Early Detection and Treatment of Head and Neck Cancer.
  • 2017

    Research Grant

    Harnessing Synergies Between 177lutate Therapy and Olaparib to Improve Clinical Outcome of Men With Metastatic Castration Resistant Prostate Cancer
  • 2014

    Journal article

    Bioinformatics pipelines for targeted resequencing and whole-exome sequencing of human and mouse genomes: A virtual appliance approach for instant deployment
    DOI: 10.1371/journal.pone.0095217
David Goode

RECENT SCHOLARLY WORKS

  • 2024

    Journal article

    Cancer cell-specific PD-L1 expression is a predictor of poor outcome in patients with locally advanced oral cavity squamous cell carcinoma
    DOI: 10.1136/jitc-2024-009617
  • 2024

    Journal article

    1616P Circulating tumour DNA (ctDNA) measurements and PET-imaging to evaluate response in a phase Ib trial of metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177-PSMA-617 (LuPSMA) plus pembrolizumab (PRINCE)
    DOI: 10.1016/j.annonc.2024.08.1697
  • 2024

    Journal article

    Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer
    DOI: 10.1002/path.6280
  • 2024

    Journal article

    Defining the challenges and opportunities for using patient-derived models in prostate cancer research
    DOI: 10.1002/pros.24682
  • 2024

    Journal article

    Clonal sweep dynamics: A marker of tumor fitness and predictor of clinical outcomes
    DOI: 10.1158/1538-7445.AM2024-2286
  • 2024

    Journal article

    Plasma ctDNA enables early detection of temozolomide resistance mutations in glioma
    DOI: 10.1093/noajnl/vdae041
  • 2023

    Journal article

    Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models
    DOI: 10.1038/s41467-023-40852-3

RECENT PROJECTS

  • 2020

    Research grants (other domestic)

    Identifying and Characterising Gene Co-Expression Modules Underlying Resistance to Androgen Deprivation Therapy in Prostate Cancer

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224